drugset / Trial / NCT04550663
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
Phase 1
Unknown
10 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
KAEDI · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
Timeline
- Start
- 2020-09-25
- Primary completion
- 2022-09-25
- Completion
- 2023-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KD-025 CAR-T cells | Cell therapy | — | — |